H. Pylori Infection
Conditions
Brief summary
To assess the efficacy and safety of Saccharomyces boulardii combined with triple therapy containing minocycline in the initial eradication of Helicobacter pylori (H. pylori) infection
Interventions
Bismuth quadruple therapy
Saccharomyces boulardii
Sponsors
Zhongda Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Aged 18-70 years, regardless of gender; 2. Positive 13C/14C urea breath test result; 3. No previous history of H. pylori eradication treatment; 4. Agreement to participate in this study and signing of the informed consent form.
Exclusion criteria
1. History of ≥ 1 instance of failed H. pylori eradication; 2. Use of antibiotics (including antibacterial traditional Chinese medicines), nonsteroidal anti-inflammatory drugs (NSAIDS), bismuth agents, H2 receptor antagonists (H2RAs), proton-pump inhibitors (PPIs), and potassium-competitive acid blockers (P-CAB) within 4 weeks before treatment; 3. Plans to conceive, pregnancy, or breastfeeding; 4. Severe liver, kidney, or cardiovascular diseases; malignancies; and alcoholism; 5. Allergies to the drugs used in this study or a history of penicillin allergy; 6. The inability to correctly express one's symptoms and wishes, such as inability due to mental illness or severe neurosis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| H. Pylori eradication rate | 7 days |
Countries
China
Contacts
Primary ContactLu Chen
Outcome results
None listed